Showing results (51-60 of 118) with videos related to

Sort By:
Pageof 12
Translational Lung Cancer Research|October 21, 2024
Efficacy of first-line immune checkpoint inhibitors in pulmonary sarcomatoid carcinomaGary Birsen, Valérie Gounant, Nicolas Girard, et al.
The Lancet. Respiratory Medicine|November 1, 2024
Nivolumab plus ipilimumab versus carboplatin-based doublet as first-line treatment for patients with advanced non-small-cell lung cancer aged ≥70 years or with an ECOG performance status of 2 (GFPC 08-2015 ENERGY): a randomised, open-label, phase 3 studyHervé Léna, Laurent Greillier, Claire Cropet, et al.
The European Respiratory Journal|May 24, 2020
First-line carboplatin plus pemetrexed with pemetrexed maintenance in HIV-positive patients with advanced non-squamous non-small cell lung cancer: the phase II IFCT-1001 CHIVA trialArmelle Lavole, Laurent Greillier, Julien Mazières, et al.
Lung Cancer (Amsterdam, Netherlands)|August 13, 2013
Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study)Alain Vergnenègre, Stéphane Hominal, Achille Edem Tchalla, et al.
Physical Chemistry Chemical Physics : PCCP|October 20, 2022
Damage in InGaN/GaN bilayers upon Xe and Pb swift heavy ion irradiationPrzemysław Jóźwik, José P S Cardoso, Diogo F Carvalho, et al.
Cancer Management and Research|January 11, 2020
Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small-Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)Alain Vergnenègre, Victor Basse, Gwenaelle Le Garff, et al.
Lung Cancer (Amsterdam, Netherlands)|October 12, 2020
Durable responses to immunotherapy of non-small cell lung cancers harboring MET exon-14-skipping mutation: A series of 6 casesMarie Mayenga, Jean-Baptiste Assié, Isabelle Monnet, et al.
The Annals of Occupational Hygiene|May 8, 2012
Pulmonary carcinoid tumors and asbestos exposureBénédicte Clin, Pascal Andujar, Issam Abd Al Samad, et al.
Cancers|March 25, 2022
Immune-Checkpoint Inhibitors for Malignant Pleural Mesothelioma: A French, Multicenter, Retrospective Real-World StudyJean-Baptiste Assié, Florian Crépin, Emmanuel Grolleau, et al.
The Oncologist|December 26, 2024
COMPOSIT study: evaluating osimertinib combination with targeted therapies in EGFR-mutated non-small cell lung cancerCamille Mehlman, Aurelie Swalduz, Isabelle Monnet, et al.
Pageof 12